Zika virus (ZIKV), a recently emerged flaviviral pathogen, has been linked to 3 microcephaly in neonates 1 . Yet, it is not understood why some fetuses develop severe 4 microcephaly due to maternal ZIKV infection while others do not. The risk for ZIKV-5 induced microcephaly is greatest during the first trimester of pregnancy in humans 2,3 , yet 6 this alone cannot account for the varied presentation of microcephaly observed. Given 7 the antigenic similarity between ZIKV and closely related dengue virus (DENV) 4 , 8 combined with the substantial immunity to DENV in ZIKV target populations in recent 9 outbreaks, we hypothesized that maternal antibodies against DENV could promote ZIKV-10 induced microcephaly. Here, using immune-competent mice, we show that maternal to 11 fetal transmission of ZIKV occurs, leading to fetal infection and disproportionate 12 microcephaly. DENV-specific antibodies in pregnant female mice enhance vertical 13 transmission of infection and result in a severe microcephaly like-syndrome during ZIKV 14 infection. Furthermore, fetal infection was promoted by the neonatal Fc receptor (FcRN).
Introduction
be detected at the site of infection and in lymphoid tissues for at least 1 week by PCR supported 1 that ZIKV infection persists long enough in immune-competent mice to allow assessment of its 2 influence on fetal development during pregnancy.
3
To address the question of whether maternal DENV immunity could enhance embryonic 4 neural complications, we infected mice of varying Flavivirus-immune status during pregnancy at 5 embryonic day (E)-7 with ZIKV (Figure 2a) . This day was chosen due to its equivalence to the 6 first trimester of fetal development in humans and since it represents a time point when the 7 mouse placenta has begun to develop, which starts around E5.5 23, 24 . We also assumed that 8 using a time point for inoculation where the placenta had not completely formed might facilitate 9 vertical transmission of infection, while the fact that decidualization has begun by this time 10 point 25 would allow us to address the potential of fetal endothelial cells to promote antibody 11 transport into the fetus. DENV induces a mild replicating infection in immunocompetent mice primary measure used to define microcephaly in humans, and observed that DENV-naïve ZIKV-1 infected dams had fetuses with slightly but significantly smaller heads compared to healthy 2 controls (Figure 2f) . However, 4G2-injected and DENV2-immune dams that were infected with 3 ZIKV had fetuses with head sizes that were substantially smaller than both naïve uninfected 4 mice and DENV-naïve ZIKV-infected mice (Figure 2f) . No significant differences in the range of 5 phenotypes were observed litter-to-litter within experimental groups and fetal demise was not 6 observed. Additional control experiments were also performed concurrently, showing that no 7 abnormalities were observed after control injection of 4G2 prior to pregnancy without maternal 8 ZIKV infection and isotype control antibodies did not influence fetal size or head circumference 9 in ZIKV-infected dams (Figure S2) . Furthermore, DENV-immune dams have normal pups 10 without any reported fetal abnormalities 31, 32 and we did not observe any reduction in fetal size 11 when 4G2-injected dams were given a challenge of DENV2 rather than ZIKV at E7 (Figure S2 ).
12
Next, we looked at the frequency of microcephaly in these fetuses (defined as a head size in the 13 3rd percentile or less for normal fetuses) and noted that while 30% of fetuses from naïve mice 14 infected at E7 with ZIKV could be assessed as having a phenotype consistent with 15 microcephaly, >90% of the fetuses of DENV2-immune or 4G2-injected dams qualified as having 16 microcephaly (Figure 2g ). This supports that maternal immunity or Flavivirus cross-reactive 17 antibodies can enhance the severity and incidence of microcephaly during ZIKV infection.
18
Due to the prominence of interferon-deficient models for studying Flaviviruses, we also 19 investigated whether interferon (IFN)-deficient mice could be used to study ZIKV infection at 20 time points developmentally analogous to the first trimester of human infection. However, even 21 with a 2-log lower inoculating dose than we used for WT mice, the infection was too severe in both the naïve and DENV-immune dams. Most dams died prior to E18 (Figure S3a ) and the 23 surviving mouse had fetuses displaying early developmental arrest ( Figure S3b ). This
24
supported that our immune competent model more clearly recapitulated the outcomes of human 25 ZIKV maternal and fetal infection than the interferon-deficient mouse model system.
To further characterize the impact of ZIKV infection, with and without maternal 1 antibodies on the development of the fetal brain in the WT mouse model, we examined the 2 brains by histology (Figure 3a, Figure S4 ). The DENV2-immune group showed profound 3 reduction in cortical thickness and loss of integrity of the expected cortical layers (Figure 3a) . In 4 particular, there appeared to be reductions in the size of the ventricular zone, intermediate zone 5 and cortical plate compared to fetuses from naïve uninfected dams and naïve ZIKV-infected 6 dams (Figure 3a) . Quantification of cortical thickness from multiple litters showed that these 7 reductions were significant and consistent for fetuses with both DENV2-immune and 4G2-8 injected dams compared to fetuses of naïve uninfected dams and naïve ZIKV-infected dams 9 (Figure 3b ). The cortical thickness was also moderately reduced in the fetuses of naïve ZIKV-
10
infected dams compared to fetuses of healthy controls (Figure 3b ), although the cortical layers 11 were intact and discernable (Figure 3a) . Since we had observed that the fetal mass was 12 decreased in all ZIKV-infected groups compared to controls (Figure 2d) , we also questioned 13 whether the reduced cortical thickness was disproportionately small relative to the body mass or 14 proportional to the body mass. Fetuses born to ZIKV exposed pregnant mothers have been 15 described as displaying both proportional and disproportional microcephaly in humans 5 . Indeed,
16
the ratio of the cortical thickness compared to the body mass for all groups showed that for 17 ZIKV-infected mice, the cortex was disproportionately reduced compared to control animals 18 (Figure 3c, S5) , indicating a presentation of disproportionate microcephaly.
19
The transcription factor Brain 1 (Brn1) is used as a marker of cortical development in 20 mice 33 ; thus, we measured levels of Brn1 in the brains of E18 embryos from all groups. We 21 observed that levels of Brn1 mRNA were reduced in fetuses from DENV2-immune or 4G2injected dams (Figure 3d) , which was correlated with the impaired cortical thickness. We also 23 measured levels of additional genes associated with early cortical neurogenesis, including fork-24 head box G1 (Foxg1), empty spiracles homologue 2 (Emx2) and Paired box 6 (Pax6).
25
Expression of these genes allows differentiation and proliferation of ventricular zone progenitors as well as expansion of the sub-ventricular zone 34, 35 . ZIKV infection resulted in reduced 1 expression of both Pax6 and Foxg1, suggesting early brain development was stunted due to 2 ZIKV infection, although Emx2 was not significantly influenced (Figure 3d ). Brain 2 (Brn2) and 3 orthodenticle homeobox protein family genes, Otx1 and Otx2, along with Brn1, aid the 4 differentiation and migration of neurons 33, 36 as well as development of neuronal layers in the 5 cortex and cerebellum 37 . ZIKV infection also suppressed the expression of both Brn2 and Otx 6 family genes. For Pax6, Brn1, and Brn2, fetuses of DENV-immune dams showed greater 7 deficits than those of naïve dams (Figure 3d ). Suppressed levels of selected cortical markers 8 were verified at the protein level by immunohistochemistry ( Figure S6 ). Together these results
9
show visually striking and quantifiable defects in the development of the cerebral cortex during 10 ZIKV infection resulting in disproportionate microcephaly, supported by evidence that cerebral 11 cortex-associated transcription factors are reduced in the fetuses of DENV2-immune dams.
12
Based on these findings and the potential of the antibody 4G2, which is DENV-directed 13 but ZIKV cross-reactive, to cause an enhanced microcephaly-like phenotype in the fetuses of 14 ZIKV-infected dams, we expected that antibodies might promote increased translocation of 15 ZIKV into the fetus; therefore, we quantified ZIKV genome copies in the fetuses on E10, 3 days 16 after the dams had been infected. This time was chosen to allow for replication of ZIKV in the 17 mother and the potential of translocation into the fetus and because it is a time point at which 18 placentation has already begun 23 . We first validated that true replication of ZIKV occurs in this (Figure 4f ).
21
To determine if ZIKV infection could be enhanced across a monolayer of FcRNexpressing endothelial cells in an antibody-dependent fashion, we using a trans-well system.
23
Human endothelial cells were cultured above a monolayer of human trophoblast cells, and supernatants containing ZIKV or ZIKV and various concentrations of 4G2 antibody were applied endothelial cell monolayers and observed no significant increase in permeability, measured by 1 trans-endothelial resistance (Figure 5i) . However, we observed an antibody-dose dependent 2 increase in infection of the trophoblast target cells on the opposite side of the trans-well insert 3 (Figure 5j) . This indicates that antibodies enhance translocation of ZIKV across FcRN-4 expressing endothelial monolayers and that ZIKV remains viable and able to infect target cells 5 following translocation.
6
We next aimed to determine if FcRN plays a functional role in enhancing ZIKV infection 7 in fetal mice. First, we validated that FcRN -/mice were able to induce anti-DENV antibodies at 8 similar titer to WT mice and observed no significant difference in the polyclonal anti-DENV 9 response (Figure 5k) . We then compared viral titers in fetuses of both naïve and DENV2-10 immune FcRN -/dams to wild-type controls. Overall, fetuses of DENV2-immune FcRN -/mice 11 showed reduced ZIKV RNA at E10 compared to the fetuses of wild-type mice (Figure 5l ).
12
Furthermore, ZIKV RNA levels were not significantly higher in the fetuses of DENV2-immune 13 dams compared to naïve dams (Figure 5l) , in contrast to the significant enhancement of ZIKV 14 infection observed in the context of DENV2 maternal immunity in wild-type animals (Figure 5l ).
15
In FcRN -/-DENV2-immune dams, only 50% of the fetal mice showed ZIKV infection, compared 16 to 100% of the fetuses of WT DENV2-immune dams (Figure 5m) . This proportion was 17 significantly lower than the proportion of infected fetuses in WT mice and not significantly 18 different from ZIKV-infected naïve WT or naïve FcRN -/mice (Figure 5m ) and suggests that
19
FcRN-mediated translocation of immune complexes increases the likelihood of vertical 20
transmission. Yet, antibodies may still have a role in enhancing titers in an FcRN-dependent 21 manner, since DENV2-immune FcRN -/fetuses that were ZIKV + showed higher viral titers than the DENV2-naïve FcRN -/fetuses that were ZIKV + (Figure 5n) . Similarly, the fetuses of wild-type 23 dams that were DENV2-immune showed higher levels of ZIKV than naïve animals after ZIKV contributions of FcRN by an alternate mechanism, we also injected dams with a blocking 1 antibody against FcRN to neutralize its function in the translocation of immune complexes 2 across the placenta. We observed that fetal head circumference was increased with FcRN 3 blockade, compared to isotype control-injection (Figure 5o) . These results support that both a 4 novel mechanism of FcRN-mediated immune complex translocation into the fetus and ADE can 5 contribute to enhanced ZIKV infection in fetal mice. profiles key for brain development. Microcephaly in humans resulting from ZIKV infection has 25 been described as both proportionate and disproportionate to the body mass 5 . In our model, we observe disproportionate microcephaly relative to the reduction in overall fetal mass, which is 1 enhanced by maternal DENV immunity. Infection was undetectable by PCR in E18 fetal brains 2 while the signs of damage to the cortex and ZIKV antigens remained. also play a strong role in the ability of antibodies raised against unique viruses to enhance 17 versus neutralize a heterologous infection, as do the concentrations of virus-specific or cross-18 reactive antibodies. Thus, future studies are also needed to examine the potential of multiple 19 strains and serotypes of DENV to enhance ZIKV-induced microcephaly since the incidence of 20 microcephaly in humans is not high enough to suggest that 100% fetuses of DENV-immune 21 mothers develop microcephaly. This study provides important considerations for microcephaly screening, raises novel therapeutic targets to limit severe disease, and informs our 23 understanding of mechanisms that could influence the severity of ZIKV presentation.
Female mice that were DENV-naïve or DENV-immune (3 weeks post-infection with 1×10 6 PFU 1 of Eden2 strain) were bred and infected with ZIKV (1×10 6 PFU of H/PF/2013 strain) on E7.
2
Detailed methods accompany the manuscript as a Supplementary Appendix.
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